Septerna, Inc., a clinical-stage biotechnology company pioneering G protein-coupled receptor (GPCR) drug discovery, reported its financial results for the second quarter ended June 30, 2026, highlighting robust revenue growth driven by its collaboration with Novo Nordisk and meaningful progress across its clinical pipeline. The company's quarterly revenue surged to $26.7 million compared to $0.1 million in the same period last year, while its net loss narrowed significantly year-over-year. With a cash position of $516.5 million, Septerna expects its existing resources to fund operations at least into 2029.

Second Quarter 2026 Financial Performance

Septerna's revenue for the quarter ended June 30, 2026, was entirely driven by its Novo Nordisk collaboration, totalling $26.7 million. This included the amortization of $14.6 million of the $195.0 million upfront payment, $0.9 million from the achievement of $4.0 million in research milestones, and $11.2 million for research services associated with the collaboration. This compares to $0.1 million from Vertex recorded in the same quarter of the prior year. The following table summarises the key income statement metrics for the quarter and the six-month period:

Research and development (R&D) expenses rose to $35.1 million for the quarter ended June 30, 2026, compared to $22.2 million for the same period in 2025, reflecting the company's expanding clinical and discovery activities. General and administrative (G&A) expenses increased to $8.5 million from $6.9 million year-over-year. Despite higher operating costs, the net loss narrowed substantially to $13.0 million from $24.8 million in the prior-year quarter, aided by interest income and other income of $4.8 million.

Balance Sheet Highlights

Septerna maintained a strong balance sheet as of June 30, 2026. The company's cash, cash equivalents, and marketable securities stood at $516.5 million, compared to $548.7 million as of December 31, 2025. Total assets were $566.7 million, while total liabilities declined to $180.0 million from $214.3 million at year-end 2025, reflecting the ongoing amortisation of deferred revenue from the Novo Nordisk upfront payment.

Pipeline Progress and Milestones

Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, commented on the quarter's progress: "We are advancing our Phase 1 study of SEP-479 and are very pleased with the observed clinical half-life, which is at the longer end of our preclinical estimates. This finding reinforces our confidence in the potential of SEP-479 as a differentiated, once-daily oral treatment for hypoparathyroidism, and we look forward to presenting SAD/MAD data in the first quarter of 2027."

The company's lead programme, SEP-479, is a potent, selective oral small molecule PTH1R agonist being evaluated in a Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial for the treatment of hypoparathyroidism. Based on pharmacokinetic data from the ongoing trial, the observed elimination half-life of SEP-479 is approximately three to four days, which the company anticipates will support once-daily dosing. To fully characterise steady-state pharmacokinetics, dosing for the MAD cohorts has been extended to 14 days, with Phase 1 data from both SAD and MAD cohorts now expected in the first quarter of 2027. During the quarter, Septerna also presented the first detailed preclinical characterisation of SEP-479 at ENDO 2026.

For SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for mast cell-driven diseases, the company previously reported positive Phase 1 clinical results, including a well-tolerated safety profile and robust, dose-dependent suppression of icatibant-induced skin wheal formation. Rather than proceeding with a Phase 2b study in chronic spontaneous urticaria (CSU), Septerna is now evaluating development strategies for capital-efficient, signal-finding clinical studies in mast cell-driven diseases with high unmet need. The company is also progressing its TSHR NAM programme toward development candidate selection, targeting potential disease-modifying oral treatments for Graves' disease and thyroid eye disease. Additionally, Septerna continues to advance its global collaboration with Novo Nordisk to discover, develop, and commercialise multiple potential oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases based on specified GPCR targets, alongside wholly-owned discovery-stage programmes utilising its proprietary Native Complex Platform®.

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on Septerna while lowering the price target to $45 from $52. This adjustment follows recent updates from other firms, as Truist Securities raised its target to $43 and HC Wainwright & Co. maintained a target of $40, all reflecting varying valuation outlooks for the NASDAQ-listed company.

Rating and Target Details

The recommendations from these firms reinforce a generally positive sentiment toward Septerna's market performance. Guggenheim's revised target of $45 is a decrease from the previous $52, while Truist's increase to $43 and HC Wainwright's steady $40 provide a range of analyst perspectives.